In silico and in vitro evaluation of imatinib as an inhibitor for SARS-CoV-2

Article activity feed

1. Version published to 10.1080/07391102.2022.2045221

   Feb 26, 2022
2. 

   Version published to 10.1101/2020.06.18.158196v2 on bioRxiv

   Aug 18, 2020
3. 

   ScreenIT

   Jun 19, 2020

   SciScore for 10.1101/2020.06.18.158196: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   NIH rigor criteria are not applicable to paper type.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Two hours post-infection, cells were washed three times with OptiMEM and replaced with medium containing anti-VSV-G neutralizing antibody (clone 8G5F11; Absolute Antibody) at a dilution of 1:50,000 to block remaining VSV-G pseudovirus.	anti-VSV-G neutralizing antibody suggested: None
   After the incubation, the cells were fixed and stained with a polyclonal rabbit anti-SARS-CoV antibody (Sino Biological; 1:500).	anti-SARS-CoV suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Vero-TMPRSS2 cell line production: Vero-TMPRSS2 cells were produced by retroviral transduction.	Vero-TMPRSS2 suggested: …

   SciScore for 10.1101/2020.06.18.158196: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   NIH rigor criteria are not applicable to paper type.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Two hours post-infection, cells were washed three times with OptiMEM and replaced with medium containing anti-VSV-G neutralizing antibody (clone 8G5F11; Absolute Antibody) at a dilution of 1:50,000 to block remaining VSV-G pseudovirus.	anti-VSV-G neutralizing antibody suggested: None
   After the incubation, the cells were fixed and stained with a polyclonal rabbit anti-SARS-CoV antibody (Sino Biological; 1:500).	anti-SARS-CoV suggested: None
   Experimental Models: Cell Lines
   Sentences	Resources
   Vero-TMPRSS2 cell line production: Vero-TMPRSS2 cells were produced by retroviral transduction.	Vero-TMPRSS2 suggested: JCRB Cat# JCRB1818, RRID:CVCL_YQ48)
   Briefly, a 70% confluent 10 cm dish of HEK-293T cells was transfected with 10μg pVSV-eGFP-dG, 2μg pCAG-VSV-N (nucleocapsid), 2μg pCAG-VSV-L (polymerase), 2μg pMD2.	HEK-293T suggested: None
   Coronavirus S pseudovirus was titrated on VeroE6 cells as described above.	VeroE6 suggested: JCRB Cat# JCRB1819, RRID:CVCL_YQ49)
   Pseudovirus-imatinib mixes were added to monolayers of 2 × 104 Vero or Vero-TMPRSS2 cells in a 96-well plate.	Vero suggested: None
   Software and Algorithms
   Sentences	Resources
   The docking file of the protein model was prepared with MGLTools v1.5.4 [26] and the molecules were docked at the RBD of the spike protein via Autodock Vina 1.1.2 [27].	MGLTools suggested: None Autodock suggested: (AutoDock, RRID:SCR_012746)
   Plates were incubated for 16 hours before quantifying GFP-positive cells using an Amersham Typhoon scanner and ImageQuant TL software.	ImageQuant suggested: (ImageQuant, RRID:SCR_014246)
   anhydrous dimethyl sulfoxide (DMSO; Sigma Aldrich)	DMSO; Sigma Aldrich suggested: None

   ---

   Results from OddPub: Thank you for sharing your code and data.

   ---

   Results from LimitationRecognizer: An explicit section about the limitations of the techniques employed in this study was not found. We encourage authors to address study limitations.

   ---

   Results from TrialIdentifier: We found the following clinical trial numbers in your paper:
   

   Identifier	Status	Title
   NCT04346147	Recruiting	Clinical Trial to Evaluate Efficacy of 3 Types of Treatment …
   NCT04357613	Not yet recruiting	IMATINIB IN COVID-19 DISEASE IN AGED PATIENTS.
   NCT04356495	Recruiting	Trial of COVID-19 Outpatient Treatment in Individuals With R…
   NCT04394416	Recruiting	Trial of Imatinib for Hospitalized Adults With COVID-19
   NCT04422678	Not yet recruiting	The Safety & Efficacy of Imatinib for the Treatment of SARS-…

   ---

   Results from Barzooka: We found bar graphs of continuous data. We recommend replacing bar graphs with more informative graphics, as many different datasets can lead to the same bar graph. The actual data may suggest different conclusions from the summary statistics. For more information, please see Weissgerber et al (2015).

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
4. 

   Version published to 10.1101/2020.06.18.158196v1 on bioRxiv

   Jun 18, 2020